Approval · Notice of Compliance 7661 · 2005
RITUXAN: Notice of Compliance 7661
Issued December 20, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7661
- Date
- December 20, 2005
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Priority
- Reason
- Additional indication for the treatment of patients with previously untreated stage III/IV folicular, cd20 positive, B-cell non-hodgkin's lymphoma in combination with cvp (cyclophosphamide, vincristine and prednisolone) chemotherapy
- Therapeutic class
- Antineoplastic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RITUXAN | Not yet assigned | — |
Medicinal ingredients
- RITUXIMAB 10 MG per ML